This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignees: Cancer Research Technology Limited, Tusk Therapeutics Ltd.. Active years: 2024.
Company Filing History:
1 out of 268 
1 out of 12 Years Active: 2024
Title: Isabelle Solomon: Innovator in Cancer Treatment
Introduction
Isabelle Solomon is a prominent inventor based in London, GB. She has made significant contributions to the field of cancer treatment through her innovative research and development of therapeutic methods. Her work focuses on enhancing the efficacy of cancer therapies, particularly through the use of antibodies.
Latest Patents
Isabelle Solomon holds a patent for a method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody. This patent describes the use of an anti-CD25 antibody that does not inhibit IL-2-CD25 interaction, which leads to enhanced binding to activating Fc gamma receptors. This mechanism results in effective depletion of tumor-infiltrating Treg cells and improved control of established tumors. Furthermore, the combination of this method with anti-programmed cell death protein-1 antibodies has been shown to further enhance tumor rejection.
Career Highlights
Throughout her career, Isabelle has worked with notable companies such as Tusk Therapeutics Ltd. and Cancer Research Technology Limited. Her innovative approaches have positioned her as a key figure in the development of new cancer therapies.
Collaborations
Isabelle has collaborated with esteemed colleagues, including Anne Goubier and Josephine Salimu, to advance her research and contribute to the scientific community.
Conclusion
Isabelle Solomon's work in cancer treatment exemplifies the impact of innovative thinking in medicine. Her patent and collaborations highlight her commitment to improving patient outcomes through advanced therapeutic strategies.